Publikationen


2022

  • Smoum R, Grether U, Karsak M, Vernall A J, Park F, Hillard C J, Pacher P.
    Editorial: Therapeutic potential of the cannabinoid CB2 receptor.
    Front Pharmacol. 2022; 13: 1039564.
  • Keller C, Rading S, Bindila L, Karsak M.
    Behavioral Studies of p62 KO Animals with Implications of a Modulated Function of the Endocannabinoid System.Cells. 2022 Apr 30;11(9):1517. doi: 10.3390/cells11091517.
  • Keller C, Yorgan TA, Rading S, Schinke T, Karsak M.
    Impact of the Endocannabinoid System on Bone Formation and Remodeling in p62 KO Mice.Front Pharmacol. 2022 Mar 22;13:858215. doi: 10.3389/fphar.2022.858215. eCollection 2022.
2021
  • Vollersen, N., Zhao, W., Rolvien, T., Lange, F., Schmidt, F. N., Sonntag, S., Shmerling, D., von Kroge, S., Stockhausen, K. E., Sharaf, A., Schweizer, M., Karsak, M., Busse, B., Bockamp, E., Semler, O., Amling, M., Oheim, R., Schinke, T. & Yorgan, T. A.
    The WNT1G177C mutation specifically affects skeletal integrity in a mouse model of osteogenesis imperfecta type XV (2021) in: BONE RES. 9
  • Dumitru CA, Brouwer E, Stelzer T, Nocerino S, Rading S, Wilkens L, Sandalcioglu IE, Karsak M. Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma.
    Cancers (Basel). 2021 May 27;13(11):2624.
  • Volk AE# ,Hedergott A#, Preising M, Rading S, Fricke J, Herkenrath P, Nürnberg P, Altmüller J, von Ameln S, Lorenz B, Neugebauer A, Karsak M #, Kubisch C#.
    Biallelic mutations in L-dopachrome tautomerase (DCT) cause infantile nystagmus and oculocutaneous albinism.
    Hum Genet. 2021 May 6. Online ahead of print. # Authors contributed equally
2020
  • Mensching L , Rading S , Nikolaev V, Karsak M.
    Monitoring Cannabinoid CB2 -Receptor Mediated cAMP Dynamics by FRET-Based Live Cell Imaging.
    Int J Mol Sci . 2020 Oct 23;21(21):E7880.
  • Yorgan TA, Rolvien T, Stürznickel J, Vollersen N, Lange F, Zhao W, Baranowsky A, Rosenthal L, Hermans-Borgmeyer I, Sharaf A, Karsak M, David JP, Oheim R, Amling M, Schinke T.
    Mice Carrying a Ubiquitous R235W Mutation of Wnt1 Display a Bone-Specific Phenotype.
    J Bone Miner Res. 2020 May 5.
2019

  • Endig J, Unrau L, Sprezyna P, Rading S, Karsak M, Goltz D, Heukamp LC, Tiegs G, Diehl L.
    Acute Liver Injury after CCl4 Administration is Independent of Smad7 Expression in Myeloid Cells. Int J Mol Sci. 2019 Nov 6;20(22). pii: E5528.
  • Karsak M, Glebov K, Scheffold M, Bajaj T, Kawalia A, Karaca I, Rading S, Kornhuber J, Peters O, Diez-Fairen M, Frölich L, Hüll M, Wiltfang J, Scherer M, Riedel-Heller S, Schneider A, Heneka MT, Fliessbach K, Sharaf A, Thiele H, Lennarz M, Jessen F, Maier W, Kubisch C, Ignatova Z, Nürnberg P, Pastor P, Walter J, Ramirez A.
    A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2.
    Hum Mutat. 2019 Aug 29.
  • Sharaf, A., Mensching, L., Keller, C., Rading, S., Scheffold, M., Palkowitsch, L., Djogo, N., Rezgaoui, M., Kestler, H. A., Moepps, B., Failla, A. V. & Karsak, M.
    Systematic Affinity Purification Coupled to Mass Spectrometry Identified p62 as Part of the Cannabinoid Receptor CB2 Interactome. (2019)
    FRONT MOL NEUROSCI. 12, S. 224
  • Mensching, L., Djogo, N., Keller, C., Rading, S. & Karsak, M. (2019)
    Stable Adult Hippocampal Neurogenesis in Cannabinoid Receptor CB2 Deficient Mice
    Int J Mol Sci. 2019 Aug 1;20(15). pii: E3759.

  • Correction: Reelin controls the positioning of brainstem serotonergic raphe neurons Shehabeldin, R., Lutz, D., Karsak, M., Frotscher, M., Krieglstein, K. & Sharaf, A. (2019) PLOS ONE. 14, 1, S. e0211849
2018

  • Shehabeldin R, Lutz D, Karsak M, Frotscher M, Krieglstein K, Sharaf A. (2018)
    Reelin controls the positioning of brainstem serotonergic raphe neurons.
    PLoS One. 2018 Jul 12;13(7):e0200268. doi: 10.1371/journal.pone.0200268. eCollection 2018.

  • Anstötz M, Karsak M, Rune GM. (2018)
    Integrity of Cajal-Retzius cells in the reeler-mouse hippocampus.
    Hippocampus. 2019 Jun;29(6):550-565. doi: 10.1002/hipo.23049. Epub 2018 Dec 18.

  • Dumitru CA, Sandalcioglu IE, Karsak M. (2018)
    Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs.Front Mol Neurosci. 2018 May 16;11:159. doi: 10.3389/fnmol.2018.00159. eCollection 2018.
2017
  • Pasquarelli, N., Engelskirchen, M., Hanselmann, J., Endres, S., Porazik, C., Bayer, H., Buck, E., Karsak, M., Weydt, P., Ferger, B. & Witting, A.
    Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS.
    Neuropharmacology. 2017 Sep 15;124:157-169.
2016
  • Nagler, M., Palkowitsch, L., Rading, S., Moepps, B. & Karsak, M.Cannabinoid receptor 2 expression modulates Gβ1γ2 protein interaction with the activator of G protein signalling 2/dynein light chain protein Tctex-1. BIOCHEM PHARMACOL.2016, 99,60-72
2010

  • Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy. 2010, 65, 698-711.

  • Karsak M, Malkin I, Toliat MR, Kubisch C, Nürnberg P, Zimmer A, Livshits G. The Cannabinoid Receptor Type 2 (CNR2) Gene is Associated with Bone Mineral Density in a Healthy Population. Hum Genet. 2009 Nov;126(5):629-36.

  • Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A. Beta-Caryophyllene is a Dietary Cannabinoid. Proc Natl Acad Sci U S A 2008, 105, 9099-104.

  • Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E, Bab I. The Cannabinoid CB1 Receptor Regulates Bone Formation by Modulating Adrenergic Signaling. FASEB J 2008, 22, 285-94.

  • Karsak M*, Gaffal E*, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tuting T, Zimmer A. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007, 316, 1494-7. (* contributed equally)

  • Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genet 2006, 38, 1184-91.

  • Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006, 103, 696-701.

  • Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434, 782-6.

  • Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A., Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005, 14, 3389-96.

  • Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005, 128, 742-55.

  • Cui XY, Hu QD, Tekaya M, Shimoda Y, Ang BT, Nie DY, Sun L, Hu WP, Karsak M, Duka T, Takeda Y, Ou LY, Dawe GS, Yu FG, Ahmed S, Jin LH, Schachner M, Watanabe K, Arsenijevic Y, Xiao ZC. NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes. J Biol Chem 2004, 279, 25858-65. (IF 5.520)

  • Hu QD, Ang BT*, Karsak M*, Hu WP*, Cui XY, Duka T, Takeda Y, Chia W, Sankar N, Ng YK, Ling EA, Maciag T, Small D, Trifonova R, Kopan R, Okano H, Nakafuku M, Chiba S, Hirai H, Aster JC, Schachner M, Pallen CJ, Watanabe K, Xiao ZC. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 2003, 115, 163-75. (IF 31.253) (* contributed equally)
FIS-Portal

Buchkapitel und Buchbesprechungen

  • Dumitru CA, Sandalcioglu IE, Karsak M.
    Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs.
    Front Mol Neurosci. 2018 May 16;11:159. Review.
  • Karsak M, Bab I, Zimmer A. New Insights into the endocannabinoid system by using cannabinoid receptor knockout mice. The Cannabinoid Receptors. Humana Press, New York. Reggio, Patricia H. (Ed.) 2009, XIV.

  • Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A. CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol 2008, 153, 286-9.

  • Karsak M and Zimmer A. Cannabinoide im Einsatz gegen Allergien: Δ9-Tetrahydrocannabinol wirkt gegen Kontaktallergien bei Mäusen. BIOforum 2007, 5/2007, 052.

  • Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handbook of Pharmacology 2005, 168: 115-142.

  • Karsak M, Hrabé de Angelis M, Zimmer A. Mausmutanten in der Schmerzforschung: Neue Erkenntnisse durch Genmutationen. Biospektrum 2002, 1.02, 17-21.